Polycythemia vera and management of the thrombotic risk: an update

Published: 20 December 2023
Abstract Views: 1368
PDF: 101
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Polycythemia vera (PV) is a chronic Philadelphia-negative myeloproliferative neoplasm caused by JAK2 mutation and characterized predominantly by the overproduction of red blood cells. The current treatment strategies of PV are based on periodic phlebotomies aimed at preventing thrombotic events associated with increased hematocrit levels. Additional therapies to mitigate the thrombotic burden, which represents the most important predictor of reduced survival in PV patients, include cytoreductive therapies, low-dose aspirin, and systemic anticoagulation. This concise review summarizes the current knowledge on the management of the thrombotic risk in PV patients.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2024;98:1465-87. DOI: https://doi.org/10.1002/ajh.27002
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021;35:3339-351. DOI: https://doi.org/10.1038/s41375-021-01401-3
Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020;42:100714. DOI: https://doi.org/10.1016/j.blre.2020.100714
Grunwald MR, Stein BL, Boccia RV, et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:788-95. DOI: https://doi.org/10.1016/j.clml.2018.08.009
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. DOI: https://doi.org/10.1016/j.mayocp.2018.08.022
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019;3:1729-37. DOI: https://doi.org/10.1182/bloodadvances.2019000211
Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol 2017;92:1131-6. DOI: https://doi.org/10.1002/ajh.24851
Landolfi R, Marchioli R, Kutti J, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24. DOI: https://doi.org/10.1056/NEJMoa035572
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224–32. DOI: https://doi.org/10.1200/JCO.2005.07.062
Mainoli B, Duarte GS, Costa J, Ferreira J, Caldeira D. Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2021;21:63-71. DOI: https://doi.org/10.1007/s40256-020-00409-x

How to Cite

Franchini, M. (2023). Polycythemia vera and management of the thrombotic risk: an update. Bleeding, Thrombosis and Vascular Biology, 2(4). https://doi.org/10.4081/btvb.2023.102